InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.
Products, services, technology
Our platform is the basis of both the proprietary project we work on and the client work that we conduct. Blending computational techniques empowered by AI, we conduct work on our own scientific projects and collaborate with clients.
Cooperation possibilities
By leveraging advanced molecular dynamics simulations, we predict dynamic drug interactions within biological systems, reducing failure risk and accelerating the development of high-potential drug candidates. InVirtuoLabs partners with Pharma and non-Pharma entities in drug discovery and design
- https://www.invirtuolabs.com
- +41 79 478 64 60
- Send an email
- Demet Olesen
Some insights
InVirtuoLabs is transforming drug discovery by cutting time, cost, and risk—bringing life-saving treatments to patients faster.
We have attracted top notch computational science, AI and machine learning talents to build a robust platform for drug discovery and design. Since inception in July 2024, we have secured CHF 2.7 mln in funding.
Our company has a wide array of skills from AI experts to biophysical simulation specialists, from former pharma executives to seasoned finance people. We have won the Boldbrain Challenge competition among 100 startups in the Canton of Ticino.
We are here to better people's life by applying AI solutions to discover novel cures for diseases.
We would like to talk to biotech investors who help us grow our company; to pharma companies who would like to partner with us for the use of our skills and technology; and to scientists in molecular science who would like us to help apply their discoveries and bring them to the market.